{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:58:54Z","timestamp":1789167534294,"version":"build-2803163510"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    A major complication of advanced prostate cancer is malignant obstructive uropathy, a condition that can precipitate post-renal acute kidney injury and ultimately require hemodialysis intervention. We present a striking imaging example of a patient with metastatic castration-resistant prostate cancer (mCRPC) and dialysis-dependent renal failure who demonstrated marked tumor regression and discontinuation of dialysis following\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA radioligand therapy.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006441","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:00:18Z","timestamp":1775487618000},"page":"e840-e841","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Discontinuation of Dialysis After \u00b9\u2077\u2077Lu-PSMA Therapy in mCRPC With Malignant Obstructive Uropathy"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-2438","authenticated-orcid":false,"given":"Enes","family":"Yerdes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebuzer","family":"Kalender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"R1-20260803","first-page":"680","article-title":"Management of obstructive uropathy in patients with advanced prostate cancer: a systematic review","volume":"32","author":"R\u00f6llig","year":"2009","journal-title":"Clin Oncol"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/end.2011.0227","article-title":"Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies","volume":"26","author":"Friedlander","year":"2012","journal-title":"J Endourol"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4274\/uob.galenos.2022.2022.10.6","article-title":"Obstructive uropathy in advanced prostate cancer","volume":"22","author":"Erbatu","year":"2023","journal-title":"Bull Urooncol"},{"key":"R4-20260803","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"17588359231177018","DOI":"10.1177\/17588359231177018","article-title":"Safety of lutetium-177 prostate-specific membrane antigen-617 radioligand therapy in the setting of severe renal impairment: a case report and literature review","volume":"15","author":"Sutherland","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.2967\/jnumed.123.265577","article-title":"177Lu-PSMA-617 therapy in a patient with chronic kidney disease","volume":"64","author":"Mercolli","year":"2023","journal-title":"J Nucl Med"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/RLU.0000000000006112","article-title":"Super responder of 177Lu-PSMA-617 PSMA therapy in patient with end-stage renal disease on hemodialysis","volume":"51","author":"Al Riyami","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1097\/RLU.0000000000003912","article-title":"Excellent response to adapted low-dose 177Lu-PSMA-617 therapy in a patient with renal compromise","volume":"47","author":"Usmani","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:02:07Z","timestamp":1785787327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006441","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"2026-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}